Antisense Therapeutics Ltd
ASX:ANP
Intrinsic Value
Antisense Therapeutics Ltd. engages in the research and development of novel antisense pharmacceuticals. [ Read More ]
The intrinsic value of one
ANP
stock under the Base Case scenario is
0.086
AUD.
Compared to the current market price of 0.084 AUD,
Antisense Therapeutics Ltd
is
Undervalued by 2%.
ANP's market price has consistently been higher than its intrinsic value.This persistent overvaluation suggests the market may be overly optimistic about
ANP or that its price is influenced by factors unrelated to fundamentals.
Antisense Therapeutics Ltd's market capitalization is 75.7m AUD.
ANP stock price is 0.084 AUD.
ANP stock price (0.084 AUD) is 2% less than its Intrinsic Value (0.086 AUD).
ANP. Open DCF Valuation
ANP.
ANP's Revenue has grown by an exceptional 1 026% over the past 12 months.
ANP's ROE (Return on Equity) has significantly decreased in the last 3 years from -49% to -73%, and is approaching profitability.
ANP's ROIC (Return on Invested Capital) has significantly decreased in the last 3 years from -671% to -1 135%, and is approaching profitability.
ANP has negative Operating Income for the last twelve months.
ANP has negative Net Income for the last twelve months.
ANP's ROE (Return on Equity) for the past 12 months is negative and is equal to -73%.
ANP's ROIC (Return on Invested Capital) for the past 12 months is negative and is equal to -1 135%.
ANP's Revenue is forecast to grow at a rate of 107% per year over the next 3 years.
ANP has negative Free Cash Flow for the last twelve months.
ANP's Revenue has been growing by an exceptional 133% per year for the last 3 years.
ANP's D/E (Debt to Equity) is very low and is equal to 0.
ANP has negative three-year average ROE (Return on Equity): -82%. The company is not efficient at transforming stockholders' equity into net income.
ANP has negative three-year average ROIC (Return on Invested Capital): -896%. The company is not efficient at using invested capital to generate operating income.
ANP's short-term assets (13m AUD) exceed its short-term liabilties (3m AUD).
ANP's long-term assets (13m AUD) exceed its long-term liabilties (3m AUD).
ANP has negative Net Debt. This means that the company has more cash and short-term investments (11m AUD) than debt (48k AUD).
ANP's Altman Z-Score is very low and is equal to -1.49.
ANP earns more than enough operating income (-11m AUD) to safely cover interest payments on its debt (-8k AUD).
Valuation Backtest
Antisense Therapeutics Ltd
Run backtest to discover the historical profit from buying and selling
ANP
stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Antisense Therapeutics Ltd
Balance Sheet Decomposition
Antisense Therapeutics Ltd
| Current Assets | 12.7m |
| Cash & Short-Term Investments | 11m |
| Receivables | 1.7m |
| Other Current Assets | 66.5k |
| Non-Current Assets | 150.8k |
| PP&E | 150.8k |
| Current Liabilities | 2.8m |
| Accounts Payable | 2.5m |
| Other Current Liabilities | 280k |
| Non-Current Liabilities | 55.1k |
| Long-Term Debt | 48k |
| Other Non-Current Liabilities | 7.1k |
Earnings Waterfall
Antisense Therapeutics Ltd
|
Revenue
|
384.9k
AUD
|
|
Operating Expenses
|
-11.8m
AUD
|
|
Operating Income
|
-11.4m
AUD
|
|
Other Expenses
|
380
AUD
|
|
Net Income
|
-11.4m
AUD
|
Free Cash Flow Analysis
Antisense Therapeutics Ltd
ANP Profitability Score
Profitability Due Diligence
Antisense Therapeutics Ltd's profitability score is 26/100. The higher the profitability score, the more profitable the company is.
Score
Antisense Therapeutics Ltd's profitability score is 26/100. The higher the profitability score, the more profitable the company is.
ANP Solvency Score
Solvency Due Diligence
Antisense Therapeutics Ltd's solvency score is 79/100. The higher the solvency score, the more solvent the company is.
Score
Antisense Therapeutics Ltd's solvency score is 79/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
ANP Price Targets Summary
Antisense Therapeutics Ltd
Shareholder Return
ANP Price
Antisense Therapeutics Ltd
| Average Annual Return | 36.13% |
| Standard Deviation of Annual Returns | 62.53% |
| Max Drawdown | -85% |
| Market Capitalization | 75.7m AUD |
| Shares Outstanding | 901 545 000 |
| Percentage of Shares Shorted |
N/A
|
Company Profile
Antisense Therapeutics Ltd
Country
Industry
Market Cap
Dividend Yield
Description
Antisense Therapeutics Ltd. engages in the research and development of novel antisense pharmacceuticals. The company is headquartered in Melbourne, Victoria. The company went IPO on 2001-12-20. The firm is engaged in developing and commercializing antisense pharmaceuticals for unmet markets in rare diseases. The firm's product candidate, ATL1103, is an antisense drug designed to block growth hormone receptor (GHr) expression thereby reducing levels of the hormone insulin-like growth factor-I (IGF-I) in the blood. ATL1103 is in clinical development for acromegaly. The firm's product candidate, ATL1102, is an antisense inhibitor targeting very late antigen 4 (VLA-4), an immune cell molecule. The firm completed a Phase IIa efficacy and safety trial of ATL1102 in multiple sclerosis (MS) patients. The firm is engaged in clinical development of ATL1102 in patients with Duchenne Muscular Dystrophy (DMD). The firm is conducting a Phase II clinical trial of ATL1102 in DMD patients.
Contact
IPO
Employees
Officers
The intrinsic value of one
ANP
stock under the Base Case scenario is
0.086
AUD.
Compared to the current market price of 0.084 AUD,
Antisense Therapeutics Ltd
is
Undervalued by 2%.
You don't have any saved screeners yet
